FDA grants orphan drug designation to NeoImmuneTechs Hyleukin7 for idiopathic CD4 lymphocytopenia treatment

FDA grants orphan drug designation to NeoImmuneTech’s Hyleukin-7 for idiopathic CD4+ lymphocytopenia treatment

Hyleukin-7 also received ODD from the European Medicines Agency in 2017, and it is the first and only agent that has obtained ODD for ICL. ICL was first

More From BioPortfolio on "FDA grants orphan drug designation to NeoImmuneTech’s Hyleukin-7 for idiopathic CD4+ lymphocytopenia treatment"